Becton, Dickenson buys TVA Medical for its access technology
Pursuing newly FDA-approved vascular access technology for patients on dialysis, Becton, Dickenson and Company has agreed to buy TVA Medical in an all-cash transaction. Terms of the sale were not disclosed.
With the acquisition, Becton, Dickenson and Company (BD) can offer the everlinQ endoAVF System, a new endovascular arteriovenous fistula technology developed by Teva Medical and approved by the FDA in June that adds to BD’s ESRD portfolio of dialysis catheters, drug-coated balloons, standard angioplasty balloons and endovascular stent graft products.
“The addition of TVA Medical
With the acquisition, Becton, Dickenson and Company (BD) can offer the everlinQ endoAVF System, a new endovascular arteriovenous fistula technology developed by Teva Medical and approved by the FDA in June that adds to BD’s ESRD portfolio of dialysis catheters, drug-coated balloons, standard angioplasty balloons and endovascular stent graft products.
“The addition of TVA Medical